New lung drug takes first step: safety check in healthy people
NCT ID NCT07225296
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This early-stage study tests a new medicine called GNS-3545 in 72 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a disease that causes lung scarring. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pharmaron CPC, Inc.
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care